-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In the latest issue of cells, a leading academic journal, the results of a clinical trial showed that the camid can also benefit older people with low immunity and prevent multiple respiratory infections safely and effectively.
based on the results, the researchers hope to use larger studies to assess the protection against new coronavirus infections.
, one of the oldest vaccines in the world, began protecting humans as early as a hundred years ago.
It is worth noting that in recent years, some new evidence shows that the card-based seedling has a wide range of stimulating effects on the immune system, not only to stimulate specific immune cells to "remember" Mycobacteria tuberculosis (the pathogen of tuberculosis), but also to continue to stimulate innate immune cells, "training" its enhanced cytokine production, rapid response to a variety of new infections.
immune action of the carcass is known to scientists as "trained immunity".
the study, scientists wanted to know whether the trained immune response caused by card-based seedlings could help the immune-weak elderly population to prevent a wide range of common infections.
, the team began a prospective randomized double-blind trial calledACTIVATE two years ago, recruiting nearly 200 subjects over the age of 65 to be given a single dose of card-based seedling or a placebo.
because of the high risk of new infections in older people, the researchers counted when and what type of new infections occurred during follow-up over the next 12 months.
-term analysis so far shows significant differences between the two groups.
in the placebo control group, 42 percent of the elderly had an infection, compared with 25 percent in the card-inoculation group, and the first infection occurred later.
from the point of view of infection type, an important observation is that compared with blood infections, urinary tract infections and other types, the protection effect of the zika seedling group against viral respiratory infections is the strongest.
the placebo group, 75 percent fewer people were infected with respiratory viruses than those in the placebo group.
" combined results show that inoculation of older people is safe and protects them from multiple infections.
illustration of this study (photo source: Reference: Reference) COVID-19 caused by the new coronavirus is also a respiratory infection, whether vaccination card seedling is also conducive to protecting the elderly from the new coronavirus infection, is a matter of concern.
because of the small sample size, the prevalence of new crowns in this clinical trial is low, so it is not possible to draw a conclusion as to whether vaccination card seedlings can prevent new crowns.
but in the discussion of the paper, the researchers noted that "the activation of the antiviral mechanism caused by the vaccination of card seedlings will reduce viral load, make the disease lighter and recover faster".
in this trial, the researchers noted: "We observed no increase in the concentration of anti-inflammatory proteins in the blood circulation of people who were vaccinated with card-mediated seedlings compared to pre-vaccination, suggesting that card-mediated seedlings did not increase steady levels of inflammation," the researchers said in the trial.
" There are several studies on the worldwide impact of card-mediated seedlings on COVID-19.
follow-up studies are expected to shed more information on whether vaccination can reduce the morbidity and mortality of new coronary infections.
. Evangelos J. Giamarellos-Bourboulis et al., (2020) Active: Randomized Clinical Trials of BCG Ingaging In Application in The Elderly. Cell. DOI: https://doi.org/10.1016/j.cell.2020.08.051.2) Elderly people protected againstst appy by BCG vaccine. Retrieved Oct. 20, 2020 from now.